Did CVDs recover post COVID-19 ?

By Staff Writer

March 31, 2023

The World Health Organization expressed concern about the disruption of essential health services for chronic disease management due to the COVID-19 pandemic. A study done in Indonesia’s Malang district, showed concerns regarding restrictions on movement and access to health services for patients with chronic conditions, such as those at high risk for cardiovascular disease. However, fears about disruptions to the supply of essential medicines were largely unfounded, as primary health centers and private suppliers had supplies of all cardiovascular medicines on hand.

While public facilities saw a significant drop in patient numbers and dispensing of CVD medicines, sales volumes at private pharmacies quickly picked up again and exceeded pre-pandemic levels within three months. Some patients who would normally get medicines free in the public sector may have been buying low-cost medicines from pharmacies during the pandemic. The response to ensuring continuity of medicine supply to CVD patients varied in different countries, with some promoting greater use of telemedicine.

However, effective control of CVD requires regular monitoring of a patient’s clinical condition, which may suffer if patients are unable or unwilling to visit health facilities. The risk of planning procurement orders annually or bi-annually was illustrated, as dramatic changes in demand can lead to shortages or over-supply.

In the Indonesian context, the private sector was able to pick up some of shortfall in CVD medicine provision reported by public services, including increasing its sales of INN and other affordable generic medicines. Were these studies replicated in other countries?

Reference url

Recent Posts

oral cancer East Africa
   

Oral Cancer in East Africa: The Need for Early Detection

💡 Did you know that Toombak use is a leading risk factor for oral cancer in East Africa?

A recent scoping review sheds light on the shocking prevalence of oral cancer in the region, emphasising the urgent need for public health interventions and improved early detection strategies. Enhancing awareness around risk factors like Toombak, tobacco, and alcohol for tackling this growing health crisis.

Curious about the key insights and their implications for health economics? Look into the full article to find out more!

#SyenzaNews #HealthEconomics #Oncology #GlobalHealth

Novartis patent cliff layoffs
     

Engineering Resilience: Mastering Pharma Patent Expiration Strategy

🚨 Are you still reacting to pharmaceutical patent expirations with layoffs and litigation, or are you ready to engineer a strategy that turns the patent cliff into your next competitive edge?

Patent expirations don’t have to derail your pharma portfolio. Learn how to outmaneuver generics and transform challenges into advantages. Dive into our latest insights and take control today.

#SyenzaNews #pharmaceuticals #innovation #PharmaStrategy #patentcliffs

diabetes medicine access
               

Improving Diabetes Medicine Access: Key Changes in the Pharmaceutical Benefits Scheme

🚀 Are we on the verge of a breakthrough in diabetes medication accessibility?

The latest updates to the Pharmaceutical Benefits Scheme (PBS) are set to transform type 2 diabetes management by expanding access to essential medicines like empagliflozin and streamlining the prescribing process for glucagon-like peptide 1 receptor agonists (GLP-1 RAs). These changes not only prioritize equity for high-risk populations but also align with global trends in cost-effective healthcare.

Dive deeper into how these revisions could reshape diabetes care and promote better health outcomes for all.

#SyenzaNews #HealthcareInnovation #healthcare #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.